|
E-mail this page to a friend!
Medicare Drug Program News
Medicare Part D Drug Prices Jumped 3.7% in Last Five
Months
Now 46% higher than prices negotiated by Department of Veteran Affairs
J une 21, 2006 - Over the past five months,
virtually all Medicare (Part D) plans raised their prices for the top
drugs prescribed to senior citizens, according to a report issued
yesterday by the health consumer organization Families USA. The report,
based on pricing data submitted by the plans to the federal government,
contradicts the Bush Administration's assertions that the new Medicare
drug program is effectively moderating rising drug costs, according to
Families USA.
The Families USA report examines Part D plan prices
for the top 20 drugs prescribed for seniors and found that:
● 100 percent of Part D plans raised their prices
for Zocor (40 mg), a cholesterol-lowering drug.
● Almost 99 percent of Part D plans raised their prices for Fosamax (70
mg), a drug used to treat osteoporosis.
● More than 97 percent of the plans raised their prices for Lipitor (10
mg), a cholesterol-lowering drug.
● More than 96 percent of the plans raised their prices for Actonel (35
mg), Toprol XL (50 mg and 100 mg), and Xalatan (0.005%, drugs used for
osteoporosis, high blood pressure, and glaucoma, respectively.
● More than 94 percent of the plans raised their prices for Celebrex
(200 mg), Nexium (40 mg), and Norvasc (5 mg), drugs used to treat pain,
gastrointestinal problems, and heart problems, respectively.
● More than 92 percent of plans raised their prices for Aricept (10 mg,)
and 89 percent raised their prices for Plavix (75 mg), drugs used for
Alzheimer's and stroke, respectively.
| |
Related Stories |
|
| |
Medicare Releases Details on Drug Plan Enrollment
Through June 11
90 percent 38.2
million) are covered – 4.4 million not covered
June 15, 2006 – Medicare yesterday released the
latest statistics on the Part D drug program, showing how many
beneficiaries are enrolled in the various plan types and other available
options. The bottom line is that 38.2 million are now receiving drug
coverage (31.8 million in Medicare, 5.4 million other sources) and 4.4
million of those eligible are not covered, including 3.2 million
estimated to be eligible for extra help.
Read
more...
New Effort Planned to Enroll Low-Income Elderly in
Medicare Drug Program
June 12, 2006 – The Social Security Administration
will spearhead a new effort to enroll low-income senior citizens –
already exempted from the late enrollment penalty - in the Medicare drug
program. The focus will be on those age 79 and over. And, on Wednesday,
the House Ways and Means Committee will begin taking a close look at the
first year implementation of the drug program, including why several
million did not enroll.
Read
more...
Read more
Medicare Drug Program
News |
|
"At the same time that the Bush Administration and
Congressional leaders are touting the effectiveness of the Medicare drug
plans, those plans are quietly raising the prices that they charge,"
said Ron Pollack, Executive Director of Families USA. "As a result,
seniors will pay more and more -- as will America's taxpayers."
According to the report, only the prices for the
generic drugs furosemide (40 mg) (a diuretic) and metoprolol tartrate
(50 mg) (a drug for high blood pressure), and the brand-name drug Zoloft
(50 mg) (an antidepressant), were not raised by a majority of the Part D
plans.
The report examined Medicare plan price changes
from mid-November 2005 (when enrollment in the new program began) to
mid-April 2006. During that time, the median price for the top 20 drugs
rose by 3.7 percent. Three of the drugs, Celebrex (200 mg), Lipitor (10
mg), and Aricept (10 mg) - rose by 6 percent or more.
One of the most significant findings in the report
is that, for 19 of the top 20 drugs, changes in the median Part D plan
prices were virtually identical to the changes in Average Wholesale
Price (AWP) established by the drug manufacturers. "This means,"
according to Pollack, "that Part D plans are doing essentially nothing
to contain the fast-rising prices by the drug industry."
The Families USA report also compared Part D plan
prices with the prices negotiated by the Department of Veterans Affairs
(VA). According to the analysis, for every one of the top 20 drugs
prescribed to seniors, the lowest price charged by any Part D plan was
higher than the lowest price negotiated by the VA. The median price
difference as of mid-April 2006 was 46 percent.
Among the biggest variations between prices
negotiated by the VA and those established by Medicare plans were the
following drugs:
● For Zocor (20 mg), the lowest annual VA price in
mid-April was $127.44, while the lowest Part D plan price was $1,275.36
- a $1,147.92 difference, or 901 percent.
● For Protonix (40 mg), a gastrointestinal agent, the lowest annual VA
price was $214.45, while the lowest Part D plan price was $1,110.96 - a
$896.51 difference, or 418 percent.
● For Fosamax (70 mg), the lowest annual VA price was $265.32, while the
lowest Part D plan price was $727.92 - a $462.60 difference, or 174
percent.
● For Xalatan (0.005%), the lowest annual VA price was $279.84, while
the lowest Part D plan price was $555.96 - a $276.12 difference, or 99
percent.
"When Congress prohibited Medicare from bargaining
for cheaper drug prices, it created a huge windfall for the drug
companies and unaffordable prices for America's seniors," said Pollack.
"It is time to correct this and to establish an effective price
negotiating system like the VA has achieved."
For a copy of the report and to review the
methodology, please visit our Web site at
www.familiesusa.org.
Families USA is the national organization for health care consumers. It
is nonprofit and nonpartisan and advocates for high-quality, affordable
health care for all Americans.
The address is 1201 New York Avenue, NW, Suite 1100, Washington, DC
20005. Phone 202-628-3030 - Fax: 202-347-2417 -E-mail:
info@familiesusa.org
Web site:
www.familiesusa.org
Source: Families USA Foundation
Click to More Senior News on the
Front Page
Copyright: SeniorJournal.com |
